Full Breakdown
Turmoil at the FDA: George Tidmarsh's Ouster and Its Implications
11/5/2025, 6:16:41 AM
Abrupt Leadership Changes at the FDA
George Tidmarsh, the head of the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER), resigned on November 4, 2025, following his placement on administrative leave amid serious allegations regarding his conduct. Tidmarsh's ousting is part of a broader pattern of instability within the FDA, which has faced significant leadership turnover and controversy in recent months. His departure came just days after the Office of the General Counsel and the Office of the Inspector General were alerted to concerns about his behavior, particularly regarding a LinkedIn post that criticized Aurinia Pharmaceuticals' drug, Lupkynis, claiming it lacked clinical benefit and had significant toxicity.
Allegations and Lawsuit
Aurinia Pharmaceuticals subsequently filed a lawsuit against Tidmarsh, alleging defamation and claiming that his statements led to a 20% drop in their stock value, resulting in over $350 million in losses. The lawsuit accuses Tidmarsh of using his regulatory position to pursue a personal vendetta against Kevin Tang, Aurinia's board chair and a former business associate. Tidmarsh allegedly attempted to solicit a bribe through his lawyer in exchange for regulatory favors, further complicating the allegations against him.
Official Responses and Support for Makary
Despite the upheaval, the White House and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. expressed their continued support for FDA Commissioner Marty Makary. HHS spokesperson Emily Hilliard emphasized the expectation of high ethical standards within the agency. Makary has been a proponent of President Donald Trump's initiatives to reduce drug costs and streamline FDA processes, but he has faced criticism from some conservative lawmakers regarding the agency's approval of a generic version of the abortion pill mifepristone.
Criticism and Opposition
The turmoil at the FDA has drawn criticism from various quarters, with some observers labeling the agency as being in "disarray." Concerns have been raised about the ethical implications of Tidmarsh's actions and the overall direction of the FDA under the current administration. Daniel Fabricant, a former FDA official, noted that any public statements by regulators can create perceptions of conflicts of interest, complicating the agency's credibility.
The Broader Impact on the FDA
The FDA has experienced significant staff reductions, losing over 1,000 employees due to layoffs and resignations in the past year. This has contributed to a decline in morale among remaining staff, who have expressed concerns about the agency's direction and leadership. Tidmarsh's resignation is seen as a symptom of deeper issues within the FDA, including a perceived shift away from scientific integrity towards political motivations under Kennedy's leadership.
Verbatim Quotes
- “It makes you wonder about judgment on other things,” — Former FDA Official
- “FDA is in crisis.” — Former FDA Official
- “In a company, this person would not see the light of day on Monday morning. Lives are at stake, and you have someone unbalanced.” — George Tidmarsh on Vinay Prasad
- “Secretary Kennedy expects the highest ethical standards from all individuals serving under his leadership and remains committed to full transparency,” — Emily Hilliard, HHS Spokesperson
What's Next
The FDA is expected to appoint a new director for CDER shortly, as the agency continues to navigate the fallout from Tidmarsh's departure and the ongoing scrutiny of its leadership and regulatory practices. The situation remains fluid, with potential implications for the agency's credibility and effectiveness in drug regulation.
